Barclays PLC Buys 84,563 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Barclays PLC lifted its position in Kura Oncology, Inc. (NASDAQ:KURA) by 104.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 165,484 shares of the company’s stock after purchasing an additional 84,563 shares during the quarter. Barclays PLC owned 0.21% of Kura Oncology worth $3,234,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. The Manufacturers Life Insurance Company increased its stake in shares of Kura Oncology by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after buying an additional 1,976 shares in the last quarter. nVerses Capital LLC bought a new stake in Kura Oncology during the 3rd quarter worth about $25,000. China Universal Asset Management Co. Ltd. increased its position in Kura Oncology by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock valued at $288,000 after acquiring an additional 5,788 shares in the last quarter. Harbor Capital Advisors Inc. raised its stake in shares of Kura Oncology by 21.9% in the third quarter. Harbor Capital Advisors Inc. now owns 47,295 shares of the company’s stock worth $924,000 after acquiring an additional 8,505 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Kura Oncology by 35.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company’s stock worth $579,000 after purchasing an additional 7,722 shares in the last quarter.

Kura Oncology Stock Up 1.6 %

Shares of NASDAQ KURA opened at $8.79 on Tuesday. The firm has a 50 day moving average price of $8.69 and a 200 day moving average price of $14.87. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The stock has a market cap of $683.55 million, a P/E ratio of -3.72 and a beta of 0.78. Kura Oncology, Inc. has a 52-week low of $6.98 and a 52-week high of $24.17.

Insider Buying and Selling

In other news, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,255 shares of company stock valued at $100,739. 5.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

KURA has been the subject of a number of research reports. TD Cowen reissued a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. Bank of America lowered their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research note on Monday, December 9th. HC Wainwright lifted their price objective on Kura Oncology from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Finally, JMP Securities restated a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a research report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $27.13.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.